A new cereblon E3 ligase modulator shows promising results with complete response in highly refractory multiple myeloma patients
At EHA 2021, Professor Sagar Lonial from the Winship Cancer Institute, Atlanta, presented results from an ongoing Phase 1/2 study in patients with relapsed/refractory multiple myeloma, treated with immunomodulatory drug iberdomid. This paves the way for phase III combination studies.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.